[Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].
OBJECTIVE
To investigate the effect and safety of zoledronic acid (Zoledex) in patients with cancer-induced hypercalcemia.


METHODS
Seventeen patients with cancer-induced hypercalcemia (corrected blood calcium > 2.70 mmol/L) were treated intravenously by 4 mg zoledex within 15 minutes on the first day. The corrected blood calcium was observed every 4 days in the following 28 days.


RESULTS
The response rate was 94.1% (16/17). The mean corrected blood calcium became normal after the first dose of zoledex (P < 0.01). The lowest value was found on the fourteenth day after treatment. The main side effects consisted of fever (29.4%, 5/17), hypocalcemic tetany (11.8%, 2/17) and arythmia (5.9%, 1/17).


CONCLUSIONS
Zoledex is effective and safe in the treatment of patient with cancer-induced hypercalcemia.
Shen
Ge
G
Department of Breast Cancer, 307 Hospital, Academy of Military Medical Sciences, Beijing 100039, China. sglh@sohu.com
Song
San-tai
ST
Jiang
Ze-fei
ZF
Bian
Shou-geng
SG
Xie
Guang-ru
GR
Wang
Ya-jie
YJ
Wang
Jie-jun
JJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D012449:Safety; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid